Biotech Test

In: Science

Submitted By lightbox
Words 675
Pages 3
Terminsprøve
Opgave 1:
b. Jo lavere pKs en syre har, jo stærkere er den.
Syers styrke angiver dens evne til at reagere med vand. pKs kan udregnes ved formlen pKs=-log⁡(Ks), hvor Ks er syrens styrkekonstant. Jo større denne værdi er jo mere af syren er omdannet til den korresponderede base og oxoniumioner. Og jo stærkere syren er jo mere reagere syren også, og det vil derfor ikke blive omdannet mere syre til den korresponderede base og oxniumioner, som betyder en højere Ks, som dermed vil give en mindre pKs, som det kan ses på formlen pKs=-log⁡(Ks).Disse ligger pKs værdier varierer mellem -7 og ca. 14. fx en Ks på 10 vil give en pKs på -1 hvorimod en Ks vil give en pKs på -0,6. Det kan virke ulogisk at en syre er stærkere jo lavere pKs da man ofte ser at jo højere et tal er, jo større eller stærkere er det også.
d. Når man fortynder en buffer, ændres pH ikke.
Et puffer er en blanding af en svag syre og en korresponderende svag base. Hvis vi kigger på en blanding af ethansyre og ethanoationer, der er i en 0,1 M opløsning. Hvis der tilsættes lidt stærk syre, vil det jo koncentration af hydroxid ioner falde og dermed også pH. H3O+aq+OH-aq←→2 H2O(l) Men imens reagerer den svage base med vandet og der bliver gendannet hydroxid ioner. Hvis man i stedet tilsætter lidt stærk base, falder koncentrationen af oxoniumioner og dermed falder pH også. Det bliver dog gendannet da den svage syre reagere med vand og gendanner oxoniumioner og fastholder altså pH. Så en svag syre og dens korresponderendes svage base kan altså fasholde pH.
Opgave 2:

1. Beskriv forløbet vist I figur 1.
Der som sker i figur 1. er at man forstyrrer transskriptionen af DNA til RNA, men hindrer altså skadelige gener til at komme til udtryk. Nogle typer vira, reovirus som bl.a. kan give diarre er opbygget er dobbeltstrenget RNA. Der er altså sket det i b at en dicer enzym, som eukaryote…...

Similar Documents

Test

...test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test vvtest test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test vvtest test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test......

Words: 50401 - Pages: 202

Biotech Business Plan

...INCYTE : BIOTECH FEST EVENT : BIOTECH BUSINESS PLAN INDIVIDUAL ENTRY : PROPOSAL : An R&D and production based organisation specialized in tissue culture and stem cell technology , skin and epidermal tissue culture and reintegration, cell-tissue-organ banking, cultivation of tissues which are compatible according to individual requirements. The venture will also have a humanitarian aspect of extending help to patients looking for organ replacement, burn victims in need of skin for skin grafting. The venture will have three intertwined multiple wings. An R& D wing to develop and improve on existing techniques, different production wings to execute the techniques, management groups to improve on marketing strategy advertising and spreding awareness. The main goal of this venture is to develop cell and tissue compatible with the recepient’s requirements and serve consumers with better availability of tissue and cell types . Easy availability will greatly increase survival rates, especially in case of burn victims who badly need skin grafting to survive. MARKETING STRATEGY : Purpose: Investments in Niche Biological Products and Services will lead to increases in export revenues of biologically-based products (apart from food products) with returns significantly above commodity levels based on global market-led and valued, research-based...

Words: 395 - Pages: 2

Valuing Biotech Companies

...Maturity Patent Expiry 100 100 50 75 48 75 85 100 100 100 100 50 38 38 18 18 14 14 11 11 11 11 -1 -1 -2 -2 -3 -7 -10 -20 -20 -15 -7 6 168 200 1 -1 -1 -2 -2 -1.5 -2.7 -3.8 -3.6 -3.6 -2.1 -1 0.66 18 22 0.11 34 37 40 43 93 135 147 336 373 552 606 774 640 371 1 Stevens used an after tax discount rate of 7.5% in this example (based on the figure used by Hambrecht & Quist) but comments that 12% may be more appropriate. It is important to appreciate that a fixed, yet low discount rate is employed. Harvard University academics, Rivette and Kline, discuss methods for assessing financial value of intellectual property and describe a “knowledge capital” discount rate as the expected rate of return for knowledge assets18. For software, biotech and pharmaceutical industries this is :“At least 10.5%”, after tax.” 18 Rivette KG & Kline D, Discovering New Value in Intellectual Property. Harvard Business Review, Jan-Feb 2000. For a decade or more we have been using a probability adjusted net present value model (developed by KPMG with Randerson’s involvement) in which probability adjustments are made to the cash flow as a consequence of each individual risk. In pharmaceutical development the risks are well defined, starting from the candidate molecule and progressing through preclinical development, Phase I, Phase II and Phase III trials. A number of sources provide statistics on transitional probabilities19. These factors relate to vaccines, new chemical entities......

Words: 5247 - Pages: 21

Test

...Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test Test test test...

Words: 10602 - Pages: 43

Biotech Internal Analysis

...Genomic Health, Inc. External Analysis Report Presented to: Dr. Karen Middleton Texas A&M University – Corpus Christi Submitted by: Jacinda Martinez Jennifer Kindred Shiwei Chen Yang Gao Ying Zhang October 16, 2013 TABLE OF CONTENTS LIST OF TABLES iii EXECUTIVE SUMMARY iv INTERNAL ENVIRONMENT 1 MISSION STATEMENT 1 FINANCIAL RATIO ANALYSIS 1 STOCK ANALYSIS 2 VRIO TEST 3 CORE COMPETENCIES 3 Research & Development 3 Patents 5 Management Team 6 Reputation 7 CURRENT BUSINESS AND CORPORATE LEVEL STRATEGY 9 Business Level Strategy 10 Corporate Level Strategy 10 STRENGTHS AND WEAKNESSES 13 Strengths 10 Weaknesses 10 SWOT MATRIX 13 REFERENCES 25 LIST OF TABLES (need to redo these for internal tables) Table 1: Strategic Group Dimensions 13 Table 2: Liquidity Ratios 14 Table 3: Leverage Ratios 15 Table 4: Activity Ratios 15 Table 5: Profitability Ratios 16 Table 6: Growth Ratios 17 Table 7: Stock Analysis 18 MISSION STATEMENT Genomic Health is dedicated to addressing the difficult challenges of cancer treatment by utilizing genomics to help physicians and patients choose the most appropriate treatment options with optimal confidence. Table 1: Nine Components of a Mission Statement Customers | Yes | Products/Services | Yes | Markets | Yes | Technology | Yes | Survival, Growth,......

Words: 5057 - Pages: 21

Test

...Test......

Words: 323 - Pages: 2

Test

...Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test Test ......

Words: 467 - Pages: 2

Test

...over it, Yorktown Technologies has the ability to produce, market, and distribute, GloFish without any opposition from any environmental group. Yorktown Technologies has authorization to sell the GloFish in the majority of the United States except in the State of California because California has state regulations banning biotech aquatic organisms. The launch of GloFish will begin as early as 2003; therefore, creating a monopoly on ornamental fish, especially the GloFish. Yorktown Technologies has patents pending virtually locking anyone from duplicating the process of genetically engineering any other fish without the approval of Yorktown Technologies. Identifying the Root Problem Components As mentioned previously, Yorktown Technologies has had several issues that have affected their marketing and distribution strategies. These areas of concern are subject to but not limited to geographical location for distribution, production, supply and demand, environmental, as well as retail outlets and its competitors. First, California has not approved the sale and/or distribution of the GloFish due to its banning of biotech aquatic organisms. California being a highly populated market makes it extremely difficult because they are a society who is willing to purchase innovative products, such as the GloFish. Furthermore, the distribution and sales of the GloFish are not approved in other countries limiting the sales and distribution for Yorktown......

Words: 1784 - Pages: 8

Biotech

...January 2014 2014 Global Biotech Outlook Differentiated Growth, Advancing Pipelines Should Drive Outperformance; Conf Call at 11am ET Today The biotech sector had a stellar 2013 (NBI: +65%; S&P: +29%) driven by strong demand for the sector’s key products, many positive phase 3 studies and a wave of successful IPOs. Looking to 2014, we think the fundamental backdrop is very similar with 1) beatable revenue growth expectations (2014e: +16% vs. 2012/2013: +12%) including several high-profile drug launches, 2) many pivotal studies set to read out and 3) a stable/favorable regulatory and reimbursement environment. Notably, these factors should continue to make biotech attractive to generalist investors, who played a major role in the 2013 outperformance. Our bias is to stick with large caps as well as mid-caps with approved products; revenue/EPS/cash flow forecasts for 2015 and beyond look broadly beatable, in our view. In contrast, we suspect that “pure pipeline” or tech platform small caps could be more volatile in 2014. We continue to believe that the biotech industry is in the early innings of an innovation cycle with many labelexpansion opportunities and novel agents in phase 2 or 3 trials that are largely unaccounted for in Street models. Hence, we are bullish on the group for 2014. Please join us for a call today at 11am ET to discuss our sector outlook/favorite names (US dial-in: 888-889-1309; OUS: 773-756-0161; Passcode: BIOTECH).  Large-cap biotech: We don’t......

Words: 13041 - Pages: 53

Biotech

...integrated biotechnology company, biotechnology start-up company, Contract Research/Manufacturing Organizations (CRO/CMO), Fuel biotechnology and Agri-biotechnology we can see what the unique properties each of these sectors have and what they share with each other. Vertically Integrated Biotechnology Company Vertical integration is the replacement of transactions in the marketplace with internal transactions within the company. Vertical integration is the result of mergers acquisitions of other companies that once supplied the parent company. It allows the company to control the economy of its products. The use of this business model has led to many advantages and disadvantages within the biotechnology industry. Vertical integration of biotech companies has offered many advantages to the growth of not only the business but also the growth of the technology offered by the company. However, growth through integration can also have many disadvantages. By examining both we can see how vertical integration plays a part in the growth of a biotechnology company. The vertical integration model has been around for many decades. Biotechnology companies apply this business model to grow and strengthen the business of the company. Vertical integration allows companies to control products from raw materials to end product. This type of business model allows the company to better manage the supply chain to ensure the product is available when the customer needs it. It......

Words: 1107 - Pages: 5

Finance Course - Hypothetical Biotech Case

...Table of Contents I. Early/mid stage biotech funding environment at a glance II. “Regenerate Biomedical” (fictional biotech company) overview a. Company milestones, stakeholders, funding to date b. Preliminary testing results for DRX c. Clinical Trials and funding needs for DRX d. Overview of Phase I Results for DRX e. Probability DRX clears phase II III. Market Overview - Hair Therapy Industry a. Market and competitive landscape b. DRX competitive advantage c. DRX Sales Forecast (three scenarios) d. Analyst Assumptions IV. Risk Profile for early/mid stage biotech companies a. Assumptions- Beta, Cost of Capital, WACC V. Overview Regenerate Biomedical funding options for DRX a. Initial Public Offering (IPO) b. Private Equity (PE) c. Big pharmaceutical company a. “Aderans” preliminary acquisition offer d. Venture Capital b. “Bio Venture” preliminary deal terms VI. Results and Conclusion a. Strategy 1 b. Strategy 2 c. Strategy 3 I. Early/mid stage biotech funding environment at a glance Biotechnology is typically defined as any science that harnesses cellular and bimolecular substances to develop new technology, drugs and products. Biotechnology has multiple applications - food alteration, genetic research, environment and energy, and human and animal health products, to name a few. Over the years, the biotech industry has produced some of the world’s greatest advances......

Words: 4652 - Pages: 19

Biotech

...are provided to illustrate the application of the various views under Issue 2 of Issue Summary No. 1, Supplement No. 1. Fact Pattern - Biotech License and R&D Contract Biotech Company (Biotech) enters into an agreement with Pharmaceutical Company (Pharma) on January 1, 20X1. The agreement includes Biotech (a) licensing certain intellectual property rights to Pharma and (b) providing research and development (R&D) services to Pharma with the objective of developing a viable drug candidate and receiving U.S. Food and Drug Administration (FDA) approval of the drug candidate. Arrangement consideration is as follows: • • Biotech receives $5 million in licensing fees upon signing the agreement Biotech receives $250,000 per year for each full-time equivalent (FTE) that performs R&D activities • Milestone Events: 1. Biotech receives $2 million upon identification of a viable drug candidate 2. Biotech receives $3 million upon successful Phase II clinical trial completion 3. Biotech receives $5 million upon FDA approval. The license and FTE fees are comparable to rates charged by Biotech in other arrangements and are also considered comparable to rates charged by Biotech's competitors and contract research organizations. None of these payments, once received, are refundable, even if FDA approval is never received. In addition, while Biotech must perform on a best-efforts basis, it is not obligated to achieve the milestones. Biotech’s analysis of its other R&D arrangements......

Words: 1563 - Pages: 7

Accounting in Biotech

...The business and scientific research domains have remained discrete to each other until recent global financial crisis. However, the economic downturn and increasing demand for alternative healthcare products have brought the paradigm shift in past couple of years. Substantial decline in federal research support have pushed scientists to find alternate ways to support their research. Across the globe these financial pressures, evolving scientific technologies and growing demand of healthcare industry turned several biomedical researchers into bioentrepreneurs. According to a latest report the Biotech industry is on track to raise $44 billion in 2011—the most ever, including the genomics bubble of 2000. Biotech indexes performed well and the private biotech sector was also up, raising $2.9 billion (1) (also see appendix: 1). Moreover, according to the recent IMS world review and McKinsey Global Institute Report, USA remains on top with 444 billion USD projected pharmaceutical markets by year 2015 (2). These emerging trends in biotechnology sector prompted several others like me to explore the path of bioentrepreneurship however, after investing my past 15 years as a pure biomedical researcher the language of accounting is as foreign to me as any biotechnological lingo for an accountant. Thus I started to acquaint myself with this new business language. I firmly believe that a journey of biomedical scientist starting from bench side (of a basic research......

Words: 318 - Pages: 2

Test

...test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test......

Words: 2025 - Pages: 9

Biotech

...sterilized forceps and weigh them to exactly 0.25 grams on weigh machine. 2) Within a minute put this samples in Mortar-pestle and add 1ml of 0.1% TCA solution as mentioned above. 3) Make the fine paste of sample and add more 0.5ml of 0.1% TCA solution to make final volume 1.5ml of sample. 4) Take this fine paste in 1.5ml centrifuged tubes and kept them on ice packs. 5) Now wipe out the Mortar-pestle first with distilled water and then with ethanol. 6) Repeat the above steps with another plant (Stressed plant). 7) Centrifuge the above paste at 15000g for 5 minutes at 4º Celsius. 8) Discard the pellet and take the supernatant in different centrifuge tube. 9) Now take 1ml of this supernatant in the test tube and add 2ml of 0.5% TBA + 20% TCA solution as prepared earlier. 10) Cover the test tube with the cotton plug. 11) Heat the above solution at 95º Celsius in water-bath for 30 minutes. 12) Divide the aliquot prepared above in two different 1.5 ml centrifuge tubes. 13) Centrifuge the above aliquot at 10000g for 10 minutes. 14) Discard the pellet and take the supernatant in centrifuge tubes.(20) Procedure for MDA estimation :- (2, 20, 21) 1) Spectrophotometry is used to measure the MDA content present in the sample . 2) Read the absorbance of different sample including both control ant stressed sample of different duration at 532nm , 600nm & at 450nm. 3) Apply the generalized formula on the absorbance measured :- MDA content = ∆ (A532nm – A600nm) / 1.56 * 105......

Words: 12095 - Pages: 49